South Korea’s health and wellness market keeps outrunning its own forecasts. Korea Tourism Organization Data Lab card records put foreign spending at Korean medical institutions and pharmacies at KRW 2.08 trillion for 2025, up 65.3% from KRW 1.25 trillion in 2024. The official patient count, released months later by the health ministry, crossed two million for the first time. Neither number was driven by the invasive surgeries Korea built its medical tourism reputation on. Both were driven by skin.
What the card data shows
KTO Data Lab tracks what foreign visitors actually charge to their cards inside Korea, and through 2025 the medical categories climbed with barely a pause. By September, foreign card spending at hospitals and pharmacies had already reached KRW 1.43 trillion, up 68% on the same period of 2024, before the full year closed at KRW 2.08 trillion. Dermatology took about 56% of that spending, with plastic surgery near a quarter, internal medicine around 10% and pharmacies most of the rest. The momentum carried straight into 2026. The Korea Times reported that total foreign card spending in Korea topped KRW 2 trillion in a single month for the first time in May 2026, up 67.1% year on year, with pharmacy spending up 206.1%, skin care and massage up 153.9% and dermatology clinics up 85.5%.
Two caveats stop me taking the card series at face value, and they cut in opposite directions. It only captures card payments, so it misses cash and the Chinese app wallets many visitors prefer, which means the true figure is higher. It also cannot tell a patient from a tourist picking up sunscreen at a Seoul pharmacy, which flatters the medical label. A series that grows 65% in a year and accelerates into the next is still telling the truth about direction, whatever the exact level.
Two million patients, one specialty
The Ministry of Health and Welfare’s official tally, announced on 24 April 2026, counted 2,011,822 foreign patients in 2025 - the first time Korea passed two million since records began in 2009, after 610,000 in 2023 and 1.17 million in 2024. Dermatology accounted for 1.31 million of them, or 62.9%, with plastic surgery at 11.2% and internal medicine at 9.2%. China supplied 30.8% of patients and Japan 29.8%; Taiwan more than doubled to a 9.2% share and the United States rose 70.4% to 8.6%. The Korea Institute for Industrial Economics and Trade put total spending by those patients and their companions at KRW 12.5 trillion, about $8.4 billion, of which KRW 3.3 trillion went on treatment itself.
The longer arc matters more than any single year. Korea Health Industry Development Institute figures cited by the South China Morning Post show 705,044 foreign dermatology patients in 2024, a 117-fold increase on 2009, when the specialty drew just over 6,000 people and 9.3% of foreign visits. It now takes more than half, and 87.7% of 2025 patient visits happened at clinic level rather than in hospitals. That is the most important fact for anyone sizing the South Korea wellness tourism market. The product has flipped from surgery you plan once to skin work you repeat, and repeat outpatient care behaves like retail rather than hospital medicine: less revenue per visit, far more visits. The gap between the KRW 3.3 trillion treatment figure and the KRW 12.5 trillion total - flights, hotels, food, shopping - is exactly why tourism officials now care more about laser clinics than transplant wards.
Gangnam density and the K-beauty pull
Seoul took 87.2% of foreign treatments in 2025, and inside Seoul the geography narrows further. The Seoul Metropolitan Government counted 999,642 international medical tourists in 2024, with Gangnam district alone receiving 377,073 of them across 1,034 registered international clinics and neighbouring Seocho another 288,475. Five districts accounted for about 92% of the city’s foreign patient visits, and Seoul has more than doubled its registered international clinics since 2020. The pull is the same engine that sells Korean skincare abroad. “K-beauty is creating new possibilities. It has evolved beyond the beauty industry to become one of Korea’s representative cultural contents,” Kang Jung-won, head of the KTO’s tourism policy bureau, told the Korea Times.
The K-beauty adjacency is this market’s moat and its ceiling at once. A visitor primed by years of Korean skincare content arrives pre-sold; the clinic closes the sale and the pharmacy next door collects the follow-on basket, which is what a 206% jump in foreign pharmacy spending looks like on a chart. But a national industry this concentrated in a few districts of one city, selling mostly one specialty, inherits a single set of risks. A safety scandal in Gangnam or a diplomatic freeze with Beijing or Tokyo would touch most of the national number at once.
The policy scaffolding is shifting
Policy is being rebuilt around this new shape of demand, and not always in the industry’s favour. On 1 January 2026 the government let its 10% VAT refund on cosmetic procedures lapse, closing a scheme that had run since April 2016 and returned KRW 146.7 billion across more than 1.2 million claims by mid-2024, according to Korea Biomedical Review. Gangnam surgeons warned the decision invites price competition from cheaper rivals, and it lands hardest on Japanese patients, who made up 43.6% of foreign cosmetic clients between 2019 and 2023. In the other direction, a May 2026 amendment to the foreign patient law legalised telemedicine for international patients from 2027, covering remote consultations before travel and follow-up care after returning home. Entry itself is rarely the obstacle. Japan, Taiwan and the United States, together more than 47% of 2025 patients, can enter visa-free for short stays, while others use the C-3-3 medical visa, and facilitators designated by the Ministry of Justice can file electronic visas for their clients, per KHIDI’s Medical Korea portal.
Read together, the two moves say the government thinks this market no longer needs subsidy, only plumbing. Letting a tax refund die while patient numbers double is a confidence bet, and probably a safe one at current growth rates. The telemedicine change is the one I would watch. Aftercare is the weakest link in a fly-in, fly-out skin business, and a legal channel for remote follow-up converts a one-off visitor into a patient a clinic can manage between trips. If Korean clinics use it that way rather than as a marketing funnel, it will do more for the market’s durability than the VAT refund ever did.
What This Means
Anyone researching the South Korea health and wellness market should be clear about what it actually is in 2026: a dermatology market wearing a wellness label, concentrated in a few square kilometres of southern Seoul and growing at rates no forecast predicted - 65.3% in card spending and about 72% in patient numbers in a single year. I would apply three tests over the next 18 months. Watch Japanese volumes through 2026 for the first clean read on whether losing the VAT refund dents the most price-conscious cohort. Watch whether telemedicine, once it takes effect in 2027, turns one-off visitors into returning patients. And watch Seoul’s 87.2% share: if it falls because regional clusters are winning patients, the market is maturing; if it falls because Gangnam stumbled, everything else will fall with it. Growth this fast in a market this narrow is real, and it is also fragile in a specific, mappable way. That is not a reason to doubt the KRW 2.08 trillion. It is a reason to remember that a number built on repeat visits can run in reverse just as quickly.
